Evidence map›Paper›PMID 39477429›Full record

ArticleIn vivo (Athens, Greece)

Accurate and Safe Tumor Targeting of Orally-administered

Sei Morinaga, Ming Zhao, Kohei Mizuta, Byung Mo Kang, Motokazu Sato, Michael Bouvet, Norio Yamamoto, Katsuhiro Hayashi, Hiroaki Kimura, Shinji Miwa and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Sei MorinagaAntiCancer Inc., San Diego, CA, U.S.A.
Ming ZhaoAntiCancer Inc., San Diego, CA, U.S.A.
Kohei MizutaAntiCancer Inc., San Diego, CA, U.S.A.
Byung Mo KangAntiCancer Inc., San Diego, CA, U.S.A.
Motokazu SatoAntiCancer Inc., San Diego, CA, U.S.A.
Michael BouvetDepartment of Surgery, University of California, San Diego, CA, U.S.A.
Norio YamamotoDepartment of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
Katsuhiro HayashiDepartment of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
Hiroaki KimuraDepartment of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
Shinji MiwaDepartment of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
Kentaro IgarashiDepartment of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
Takashi HiguchiDepartment of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
Hiroyuki TsuchiyaDepartment of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
Satoru DemuraDepartment of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
Robert M HoffmanAntiCancer Inc., San Diego, CA, U.S.A.; all@anticancer.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimSalmonella typhimurium A1-R has been shown to target and inhibit many types of cancers in mouse models without continuous infection of normal tissue. The objective of the present study was to determine the effective dose of orally-administered Salmonella typhimurium A1-R, expressing-green fluorescent protein (GFP), on an HT1080 human-fibrosarcoma nude-mouse model. MATERIALS AND

methodsThe HT1080-human- fibrosarcoma nude-mouse models were randomized into the following three groups: G1: untreated control; G2: Oral Salmonella typhimurium A1-R (5×10

resultsSalmonella typhimurium A1-R was administered orally at a dose of 3.3×10

conclusionThe present study showed that an aggressive fibrosarcoma could be regressed by orally-administered Salmonella typhimurium A1-R which accurately targeted tumors without continuous growth in normal organs. The present results suggested the potential of orally-administered Salmonella typhimurium A1-R as a probiotic to treat aggressive soft-tissue sarcoma.

Indexed as

FibrosarcomaGreen Fluorescent ProteinsMice, NudeSalmonella typhimuriumAdministration, OralAnimalsCell Line, TumorDisease Models, AnimalHumansMiceTumor BurdenXenograft Model Antitumor AssaysGreen Fluorescent Proteinsfibrosarcomagreen fluorescent proteinHT1080nude miceoral administrationSalmonella typhimurium A1-Rtumor regressiontumor-targeting

Identifiers

PMID39477429
PMCPMC11535920

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.